

1 *Review*

2 **Pathogen at the Gates: HCMV Entry and Cell** 3 **Tropism.**

4 **Christopher C. Nguyen¹ and Jeremy P. Kamil^{1, #}**

5 ¹Department of Microbiology and Immunology, Louisiana State University Health Sciences Center,
6 Shreveport, Louisiana, USA

7 Address correspondence to Jeremy P. Kamil, jkamil@lsuhsc.edu; 1501 Kings Highway, Shreveport, Louisiana
8 71103

9

10 **ABSTRACT:** The past few years have brought substantial progress toward understanding how
11 human cytomegalovirus (HCMV) enters the remarkably wide spectrum of cell types and tissues
12 that the virus is observed to infect. Neuropilin-2 and platelet-derived growth factor receptor alpha
13 (PDGFR α) were identified as receptors, respectively, for the trimeric and pentameric glycoprotein
14 H / glycoprotein L (gH/gL) complexes that in large part govern HCMV cell tropism, while CD90
15 and CD147 were also found to play roles during entry. X-ray crystal structures for the proximal
16 viral fusogen, glycoprotein B (gB), and for the pentameric gH/gL complex (pentamer) were solved.
17 A novel virion gH complex consisting of gH bound to UL116 instead of gL was described, and
18 findings supporting the existence of a stable complex between gH/gL and gB were reported.
19 Additional work indicates that the pentamer promotes a mode of cell-associated spread that resists
20 antibody neutralization, as opposed to the trimeric gH/gL complex (trimer), which appears to be
21 broadly required for the infectivity of cell-free virions. Finally, viral factors such as UL148 and
22 US16 were identified that can influence the incorporation of the alternative gH/gL complexes into
23 virions. We will review these advances and their implications for understanding HCMV entry and
24 cell tropism.

25 **KEYWORDS:** Viral entry; viral glycoproteins; virus receptors; UL148; US16; UL128-131; gB; gO;
26 PDGFR α , integrins; Nrp2; gH/gL; cytomegalovirus; herpesviruses; HCMV; CMV; pentamer; trimer;
27 glycoprotein H; glycoprotein L; glycoprotein O; glycoprotein B; UL128; UL130; UL131A; UL131
28

29 HCMV exhibits a broad cell tropism that is reflected in the multifarious tissues and organs in
30 which the virus is observed to cause clinical disease. Despite evidence that the virus alters its gH/gL
31 complexes in a manner that depends on the cell type producing virus [1], the regulation of HCMV
32 cell tropism is poorly understood. This review will focus on HCMV cell tropism as it relates to the
33 viral entry machinery found in the virion envelope. Over the last several years, substantial progress
34 has been made in this area. A number of new cellular receptors have been identified, and in two
35 key examples, the newly identified cellular receptor is matched to a specific gH/gL complex.
36 Furthermore, a new gH complex has been characterized, and a number of viral factors that contribute
37 to strain-specific differences in cell tropism have been described. Although there remain important
38 unresolved questions, these advances provide a new level of clarity for understanding HCMV cell
39 tropism, and suggest new models to explain how HCMV enters cells and spreads within tissues.

40 **Viral envelope glycoprotein complexes and receptors**

41 Before the first complete HCMV genome sequence was published in 1990 [2], three major
42 disulfide-linked viral envelope glycoprotein complexes had been described [3-5]. These complexes,
43 originally designated as gC-I, gC-II, and gC-III, have turned out to play crucial roles in HCMV entry.
44 The viral genes encoding the constituents of each complex are now known, as are the relationships

45 to the conserved entry machinery shared among all herpesviruses. Therefore, the complexes are
46 increasingly referred to by the terms shared across the Herpesviridae, e.g., glycoprotein H /
47 glycoprotein L (gH/gL), glycoprotein B (gB), glycoprotein M / glycoprotein N (gM/gN). In certain
48 examples in which a gene product is found only among beta-herpesviruses or is unique to HCMV,
49 the name of that product is often used, e.g. gO (UL74) in the case of gH/gL/gO for trimer, or UL116
50 in the case of gH/UL116, the newly discovered gH complex with UL116 [6].

51 **gB**

52 gC-I is made up of homotrimers of glycoprotein B (gB), a pan-Herpesviridae conserved
53 glycoprotein that is posited to serve as the proximal mediator of membrane fusion events during viral
54 entry. The three-dimensional structures of post-fusion gB from herpes simplex, HCMV, and the
55 Epstein-Barr virus resemble those of glycoprotein G from the rhabdovirus vesicular stomatitis virus
56 (VSV G), and of gp64 from the *Autographa californica* nuclear polyhedrosis virus, a baculovirus [7,8].
57 Together, VSV G, gp64, and gB comprise the class III membrane fusogens [9]. Based on inferences
58 from the prefusion structure of VSV G, gB is thought to dramatically rearrange during membrane
59 fusion. The pre-fusion gB is posited to be a relatively flattened conformer, in which the fusion loops
60 are positioned at the base of the homotrimer, close to the viral membrane and hence tucked away
61 from the target membrane and set apart from one another. In the prevailing model, fusion occurs
62 via a transitory intermediate in which the fusion loops reach out to the target membrane [9]. In the
63 post-fusion configuration, three central helices line up at the core of the homotrimer, elongating the
64 structure, causing the fusion loops to cluster closer together at the side of the homotrimer opposite
65 from where they began [10].

66 HCMV gB, which is encoded by *UL55*, is synthesized as a 160-kD precursor that undergoes furin
67 cleavage in the Golgi, resulting in 116 kD and 55 kD fragments that remain disulfide-linked to each
68 other [11]. In 2015, two crystal structures for HCMV gB ectodomain were published, one at 3.8 Å
69 resolution, and another at 3.6 Å, in which the ectodomain is bound to the Fab portion of a neutralizing
70 antibody [8,12]. A number of cell surface proteins have been reported or implicated as receptors for
71 gB, including the epidermal growth factor receptor (EGFR)[13], the platelet-derived growth factor
72 receptor alpha (PDGFR α)[14], and, as discussed further below, integrins [15,16]. On the other hand,
73 it has also been suggested that gB functions as a viral fusogen that does not bind cellular receptors
74 [17]. In light of the latter, attempts to visualize interactions between gB and its putative receptors
75 by approaches such as cryo-electron microscopy (cryo-EM) would seem warranted.

76 **gM/gN**

77 gC-II is comprised of a disulfide linked heterodimer of glycoproteins M (gM) and N (gN), which
78 are encoded by *UL100* and *UL73*, respectively [18,19]. gM/gN is the most abundant glycoprotein
79 complex on virions [20,21], and is essential in HCMV, as null mutants are non-viable. The gM/gN
80 complex plays key roles during attachment to host cells, likely by mediating interactions with
81 heparan sulfate proteoglycans on the cell surface [22]. Notably, gM/gN also plays intracellular roles
82 during viral replication that are independent of its roles in attachment [23,24]. gM is an N-
83 glycosylated 48-kD type III transmembrane (TM) glycoprotein with seven predicted TM helices,
84 while gN is single-pass type I TM protein that is extensively O-glycosylated. The unmodified 138
85 amino acid gN polypeptide in strain AD169 specifies a molecular weight of approximately 18-kD
86 when expressed on its own, however the fully glycosylated (mature) form detected from virion
87 lysates migrates at ~65-kD in sodium dodecyl sulfate polyacrylamide gel electrophoresis [18,19].
88 Motifs in the gM cytoplasmic tail are required for trafficking during virion assembly [23], and the
89 cytoplasmic tail of gN, which is palmitoylated at two different cysteine residues, is required for
90 secondary envelopment [24]. The gN coding sequence varies remarkably across HCMV strains
91 [25,26], consistent with the observation that gM/gN is an important target for humoral immune
92 responses [27].

93 **The Trimeric gH/gL Complex and Its Receptors**

94 gC-III, now frequently referred to as “the trimer” or “gH/gL/gO,” is a heterotrimeric complex in
95 which the heterodimer of gH (*UL75*) and gL (*UL115*) is disulfide linked to glycoprotein O (gO), a
96 heavily N-glycosylated polypeptide encoded by *UL74* [28-30]. All herpesviruses encode gH/gL
97 complexes, as gH/gL and gB together comprise the “core” herpesvirus membrane fusion machinery.
98 Homologs of gO, in contrast, are found only among betaherpesviruses. The emerging consensus is
99 that gO, in the context of the trimer, is absolutely required for the infectivity of cell-free virions [31,32].
100 The platelet-derived growth factor receptor alpha (PDGFR α) was identified in three different
101 independent studies to function as a cellular receptor for the trimer [33-35]. This finding has
102 continued to find support in the literature [36,37].

103 The latest data suggest that tyrosine kinase activity of PDGFR α is dispensable for its role in
104 HCMV entry [34,36]. The severely defective phenotypes observed during infection of fibroblasts
105 lacking PDGFR α phenocopy those seen with gO-null mutant viruses, with the residual low-level
106 infectivity being pentamer-dependent [31,34-36,38]. Thus, a role for PDGFR α in trimer-dependent
107 entry may explain why the trimer is required for cell-free HCMV virions to infect fibroblasts, which
108 ordinarily express PDGFR α . However, why gO is required for cell-free virions to infect epithelial
109 or endothelial cells remains unclear, since these cell types either do not express PDGFR α [34] or
110 express it in only low amounts that are not required for soluble recombinant trimer to bind to cells
111 [39]. Additional hitherto unidentified cellular receptors, or perhaps, receptor-independent roles in
112 membrane fusion may explain why the trimer is required for the infectivity of cell-free virions in cells
113 that lack PDGFR α .

114 **The Pentameric gH/gL Complex and Its Receptors**

115 In 2005, a second HCMV gH/gL complex, now often referred to as “pentamer,” was discovered
116 after the repair of a frame-shift mutation in *UL131* (*UL131A*) dramatically expanded the cell tropism
117 of the laboratory-adapted HCMV strain AD169, restoring its infectivity for epithelial and endothelial
118 cells [40,41]. The pentamer is composed of a gH/gL heterodimer bound to a trio of small
119 glycoproteins encoded by *UL128*, *UL130*, and *UL131* (or as some refer to it, *UL131A*) [28,41-43]. The
120 *UL128-131* locus was observed to be (i) unstable during HCMV passage in fibroblasts [44], and (ii)
121 required for infection of leukocytes, dendritic cells, and endothelial cells [45-48]. The latter
122 observations may have also hastened the discovery of the pentamer.

123 In 2015, a group from GSK Vaccines further defined the assembly of the pentamer. These
124 investigators identified that the cysteine at amino acid position 144 (Cys144) of the gL polypeptide
125 chain forms a disulfide bond to either Cys162 of *UL128* or Cys351 of gO [28]. This finding explains
126 why the two gH/gL complexes are mutually exclusive. The same study provided low resolution
127 cryo-EM images of recombinant pentamer and trimer bound to gH antibodies. Similar cryo-EM
128 approaches were taken to characterize neutralizing antibody binding sites [49].

129 In 2017, x-ray crystal structures for the pentamer bound to two different neutralizing antibodies
130 were reported at 3.0 Å and 5.9 Å [43]. Several aspects of the gH domain structure closely resemble
131 Epstein Barr virus (EBV) gH, while the overall structure is nonetheless described as an intermediate
132 between the “rod-like” conformation of herpes simplex virus-2 gH/gL and the “boot-like” one seen
133 for EBV gH/gL. Two disulfide bonds connect the N-termini of gH and gL to each other: gH Cys59 to
134 gL Cys54, and gH Cys95 to gL Cys47. As predicted from the literature [44,45,50-53], *UL128*, *UL130*
135 and a C-terminal region of gL adopt chemokine folds; of the CC type for gL and *UL128*, and of the
136 C- type for *UL130*. This observation suggests that the ancestral cytomegalovirus “pirated” host
137 chemokine genes on multiple occasions. Of course, integration of chemokines into the viral cell
138 entry machinery could provide receptor binding and signaling properties that could be immediately
139 advantageous to the virus, although some of these features may ultimately be lost or modified during
140 evolution.

141 Another striking aspect of the pentamer structure is how *UL128* connects to gL. A ~40 amino
142 acid region of *UL128*, comprising residues 123 to 162 of the primary sequence, forms a surprisingly
143 long (~50 Å) flexible linker that stretches across *UL130* and *UL131* to reach gL, at which point it makes
144 three alpha helical turns and presents Cys162 to form its disulfide linkage to Cys144 of gL [43]. It is

145 fascinating to consider in what order the subunits of pentamer must assemble for UL128 to adopt this
146 peculiar final conformation.

147 Earlier this year, neuropilin-2 (Nrp2) was convincingly identified as a functional cell entry
148 receptor for the pentamer [37]. To identify Nrp2, the study made use of a high-throughput “avidity-
149 based extracellular interaction screen” (AVEXIS), in which recombinant single-pass transmembrane
150 proteins were monitored *in vitro* for interactions with recombinant trimer and pentamer. After
151 identifying a high-affinity interaction between Nrp2 and pentamer, the investigators demonstrated
152 that Nrp2 is essential for pentamer-dependent HCMV infection of endothelial and epithelial cells.
153 The screen also identified interactions of trimer and pentamer with other cellular molecules that may
154 represent additional receptors. For trimer, the additional hits included transforming growth factor
155 beta receptor type 3 (TGF β RIII) and neuregulin-2 (NRG2). For pentamer, the additional high-
156 affinity interaction hits were thrombomodulin (THBD), leukocyte immunoglobulin-like receptor
157 subfamily B member 3 (LILRB3) the immunoglobulin alpha Fc receptor (FCAR). Another hit for
158 pentamer, though of lower affinity, was CD46. Although the biological relevance for these other
159 hits remains to be established, it seems likely that at least some of the molecules will turn out to play
160 roles during natural infection.

161 Additional Receptors

162 CD147 was recently shown to be required for pentamer-dependent entry into epithelial cells,
163 however, in a manner that does not involve a direct interaction with the pentamer [54]. Entry of
164 Lujo virus, an arenavirus, requires Nrp2 as a surface receptor but also requires CD63, a tetraspannin
165 protein, as an intracellular factor for entry [55]. Notably, another tetraspannin, CD151, was also
166 recently reported to play roles during HCMV entry [56]. By analogy, it seems plausible that Nrp2
167 functions as the proximal cell surface receptor for the pentamer, while other molecules, such as
168 CD147 or CD151, are required as co-receptors that act later— perhaps at a post-internalization step,
169 during entry.

170 Another cellular molecule recently implicated as an HCMV receptor is THY-1 (CD90), which
171 reportedly interacts with both gH and gB [57,58]. THY-1 engages $\alpha v \beta_3$ integrins and recruits the
172 signaling adaptor molecule paxillin during signaling. The $\alpha v \beta_3$ integrins reportedly function gH-
173 dependent co-receptors during entry [59], and paxillin has been found to be important during entry
174 into monocytes [60]. Notably, integrins α_2 , α_6 , and β_1 are also reported to play roles during HCMV
175 entry at a post-attachment step [15,16]. The interactions with integrins are thought to involve a
176 “disintegrin-like” gB motif that resembles motifs found in the integrin binding domain of cellular
177 proteins of the “a disintegrin and a metalloproteinase” (ADAM) family. Nonetheless, the
178 disintegrin-like motif is mostly buried in the post-fusion gB structure [12]. A pre-fusion gB structure
179 would help to shed further light on the role of this motif in entry.

180 Many are called, few are chosen?


181 Over the years, a great many different cell surface proteins have been reported to function as
182 HCMV entry receptors. Considering the plethora of different cell types that the virus infects, it
183 seems plausible that many if not all of these molecules play *bona fide* roles in early events during
184 infection. That said, it does seem likely that certain cell surface molecules serve as the “primary
185 receptors” that are required for the proximal events that drive physiologically default modes of entry,
186 even though these default modes of entry appear to differ between different types of target cells.
187 PDGFR α can likely be considered a primary receptor for trimer-dependent entry into fibroblasts,
188 since wild-type virus is profoundly defective for entry into fibroblasts under conditions where
189 PDGFR α is absent or unavailable, and pentamer-null virus shows a more severe, virtually absolute
190 entry defect in these settings[33-36]. Based on the evidence, Nrp2, too, should be considered
191 primary receptor for pentamer-dependent entry into epithelial and endothelial cells [37].

192 Receptors and co-receptors for viral entry often function at steps that are both temporally and
193 spatially distinct from each other [61]. For instance, a given receptor may interact with a viral
194 glycoprotein complex at the cell surface to promote endocytosis of virions, while another cellular

195 factor may be required for membrane fusion and escape from the endocytic compartment. Thus,
 196 although the evidence for co-receptors is less straightforward, other cellular factors may turn out to
 197 absolutely required for downstream events during entry, or may serve in secondary or tertiary roles,
 198 in which one of any number of different cellular molecules could substitute. It also seems likely that
 199 certain cell surface proteins increase the efficiency of entry but are not required for infection to occur.

200 Of course, the cell type being infected has important implications for the mechanistic details at
 201 play. Trimer-dependent entry into fibroblasts is rapid, does not require clathrin, and is pH-
 202 independent, which suggested this mode of entry involved fusion at plasma membrane [62,63] (FIG
 203 1). According to the latest data, however, trimer-dependent entry into fibroblasts occurs through a rapid
 204 macropinocytosis [64]. Pentamer-dependent entry into epithelial and endothelial cells, on the other
 205 hand, requires low pH, and presumably involves a more prolonged form of endocytosis [63].

206 The literature has made clear that pentamer and trimer drive entry into different cell types via
 207 distinct cell surface receptors, which strongly suggests that there are at least two major modes of HCMV
 208 entry: pentamer-dependent and trimer-dependent [33,34,37,65]. Each mode likely involves a unique
 209 set of cellular proteins that play roles as receptors, co-receptors, or as accessory factors that enhance
 210 infection, and the details for a single mode of entry may differ somewhat between cell-type, for
 211 instance pentamer-dependent entry into epithelial cells versus endothelial cells may rely on distinct
 212 co-receptors, even if Nrp2 is a primary receptor in both settings.



213

214 **FIGURE 1. Receptors for HCMV gH/gL complexes.** The trimeric gH/gL/gO complex interacts
 215 with PDGFR α to drive a pH-independent mode of entry that involves macropinocytosis. The
 216 pentameric gH/gL/UL128-131 complex interacts with Nrp2 to access a mode of entry that involves
 217 endocytosis and a decrease in pH. CD147 has been identified as a co-factor for this mode of entry.
 218 Note: gB is depicted as a homotrimer labeled as "B". See text for additional details.

219 How do gH/gL complexes regulate membrane fusion?

220 It is assumed that upon recognition of the appropriate cell surface receptor, gH/gL complexes
 221 trigger gB to fuse virion and target cell membranes. Precisely how gH/gL complexes regulate the
 222 gB fusogen is nevertheless unclear. Data suggesting a physical interaction between gH/gL and gB
 223 come mainly from experiments with herpes simplex virus [66-68]. A recent HCMV study, however,
 224 reported co-immunoprecipitation (co-IP) results which suggest a stable complex between gB and
 225 gH/gL occurs in infected cells and in virions [69]. Future studies leveraging structural and
 226 biophysical approaches will be needed to illustrate how gB is regulated in response to gH/gL
 227 interactions with cellular receptors. Regardless, since the trimer is observed to be indispensable for

228 infection all cell types, it has been argued that pentamer may stimulate endocytosis of virions, while
229 the actual membrane fusion may require the trimer to activate gB [32].

230 Cell-associated versus cell free spread

231 HCMV is thought to disseminate within the host primarily through cell-to-cell spread rather
232 than via release of extracellular “cell-free” virions that would be susceptible to antibody responses.
233 Most of the infectious virus in the blood of seropositive and acutely infected patients is found in the
234 leukocyte compartment rather than plasma or serum [70-72]. Furthermore, clinical isolates of
235 HCMV spread in a highly cell-associated manner during initial tissue culture passages [73,74], and
236 the progressive loss of this cell-associated phenotype correlates with disruption of several elements
237 within the viral genome [73,75]. We consider the major viral genes known to impact cell-associated
238 vs cell-free spread below.

239 *RL13*

240 *RL13*, which encodes a virion envelope glycoprotein, is among the viral genes that most rapidly
241 mutate during tissue culture propagation of the virus, often acquiring nonsense or frameshift
242 mutations after one to four passages on fibroblasts, endothelial cells, or epithelial cells [75,76].
243 Cultured fibroblasts infected with HCMV harboring repaired *RL13* and *UL128-131* loci produce
244 remarkably small amounts of cell-free infectious virus until several weeks post-infection [75,76].
245 These observations may suggest a function of *RL13* in the dampening of HCMV spread *in vivo*,
246 perhaps to promote long-term persistence, or alternatively, may reflect a mode of selection peculiar
247 to laboratory tissue culture conditions. Unfortunately, little is known about the function of *RL13*.
248 Ectopically expressed *RL13* has been shown to traffic to the cell surface and bind the Fc domain of
249 IgG₁ and IgG₂ antibodies, followed by internalization [77]. These findings may be taken to imply an
250 immune-evasive function for *RL13*, though *RL13*-dependent internalization of IgG has to date not
251 been demonstrated in the context of the infected cell. *RL13* has also been shown to strongly suppress
252 the contribution of gO to cell-free spread in a *UL128*-null Merlin background [78]. Although these
253 findings shed light on the potential interactions of *RL13* with cellular and viral factors, they do not
254 readily explain the pronounced instability of *RL13* during tissue culture propagation of HCMV.

255 *gH/gL complexes and cell tropism*


256 The literature suggests that cell-free versus cell-associated modes of spread are governed in large
257 part by the composition of gH/gL complexes expressed in the virion envelope. Repair of the
258 pentamer was observed to increase the cell-associated nature of the virus [46], and a more recent
259 study showed that the pentamer drives a mode of direct cell-to-cell spread that resists neutralization
260 by antibodies [79]. Accordingly, repair of the pentamer in strain AD169 promotes the formation of
261 syncytia during *in vitro* cultivation of the virus [40]. On the other hand, the trimer is required for
262 the infectivity of cell-free virions [31,38]. Although one might assert that the pentamer promotes
263 cell-associated modes of spread and that the trimer enhances cell-free spread, the pentamer is
264 nonetheless required for cell-free virions to efficiently infect endothelial and epithelial cells, as well
265 as monocytes. Another observation that would confound generalizing the trimer and pentamer into
266 respective roles in “cell-free” versus “cell-to-cell spread” roles is that HCMV strain AD169 deleted
267 for the essential tegument protein pp28 (*UL99*) was found to spread efficiently in cultured fibroblasts
268 [80]. Because strain AD169 harbors a frameshift in *UL131* that renders it unable to express pentamer,
269 the efficient spread observed for the pp28-null virus has led some to argue that the trimer may suffice
270 to drive cell-to-cell spread in fibroblasts [36].

271 Viral genes and polymorphisms that impact HCMV cell tropism

272 HCMV strains show large differences in the relative levels of pentamer and trimer incorporated
273 into virions, and these differences correlate with cell tropism differences between strains [32,81]. A
274 number of HCMV genes have the capacity to influence viral cell tropism at the stage of entry, and

275 most of these presumably act via effects on the composition of gH/gL complexes that are incorporated
 276 in virions. Certain HCMV strains that maintain intact or largely-intact ULb' regions express the
 277 pentamer at low levels. Examples include viruses derived from BAC-clones of strains TR [82],
 278 TB40/E [83] and VR1814 /FIX [84]. These strains, at least when reconstituted on fibroblasts, express
 279 high levels of gH/gL/gO (trimer) and low levels of gH/gL/UL128-131 (pentamer). Although a
 280 mutation in an intron of *UL128* has been identified to limit pentamer expression in strain TB40/E [85],
 281 why FIX and TR express similarly low levels of pentamer is unknown. Given their low levels of
 282 pentamer expression, it is perhaps unsurprising that these HCMV strains replicate inefficiently on
 283 epithelial cells [40]. On the other hand, the highly passaged strain AD169, which carries a ULb'
 284 region that has undergone rearrangements and deletions leading to loss of ~12 kbp of coding content,
 285 replicates robustly on epithelial cells when pentamer expression is restored [40].

286 Intriguingly, ablation of *UL148*, a gene within the ULb' , enhances the ability of FIX, TR, and
 287 TB40/E to replicate to high levels on ARPE-19 epithelial cells, and leads to a striking reduction in
 288 overall levels of gH/gL and of trimer in virions [[86,87] and Siddiquey, M. and Kamil J.P. unpublished
 289 results] (FIG. 2). The *UL148*-null phenotype in these strains is accompanied by markedly reduced
 290 expression of gO, which likely explains why the *UL148*-null mutants express low levels of trimer.
 291 Nonetheless, the increase in epithelial cell tropism does not appear to involve enhanced levels of
 292 pentamer expression.



293

294 **FIGURE 2. Regulation of alternative gH/gL complexes by UL148.** UL148, a viral endoplasmic
 295 reticulum (ER)-resident glycoprotein, promotes high level expression of the trimer during infection
 296 ($UL148^+$) by stabilizing gO within the endoplasmic reticulum, resulting in the production of trimer-
 297 rich progeny virions. In *UL148*-null infections ($UL148^-$), virions with lower levels of trimer are
 298 produced, which are observed to more efficiently infect and replicate in epithelial cells. See text for
 299 additional details.

300

301 We recently reported that gO, but not other viral glycoproteins, is intrinsically unstable within
 302 the ER and is constitutively targeted for ER-associated degradation (ERAD) during infection [87].

303 UL148 appears to reduce the rate at which gO is degraded, possibly by interacting with SEL1L, a core
304 component of the ERAD machinery. The observation that gO behaves as a constitutive ERAD
305 substrate suggests that modulation of ERAD could provide a platform for viral regulation of cell
306 tropism in HCMV and perhaps other betaherpesviruses. Nonetheless, whether UL148 is somehow
307 regulated to stabilize gO in a cell-type specific manner remains to be seen.

308 Interestingly, UL148 was also recently identified to prevent surface presentation of CD58 (LFA-
309 3), a co-stimulatory ligand for natural killer cells and T-cells [88], and to strongly contribute to the
310 induction of the unfolded protein response (UPR) during infection [89]. It is not yet clear how roles
311 for UL148 in CD58 retention or stabilization of gO relate to the mechanism by which it activates the
312 UPR. However, pharmacologic and short interfering RNA treatments that inhibit or deplete the
313 ERAD machinery stabilize gO expression [87]. Since blockade of ERAD would also be expected to
314 activate the UPR, it seems reasonable to hypothesize that UL148 functions in part by inhibiting ERAD.

315 US16 is another viral factor that was recently identified to impact the composition of gH/gL
316 complexes in HCMV virions [90]. *US16*-null mutant viruses fail to incorporate pentamer into
317 progeny virions, and accordingly, are unable to efficiently infect epithelial cells or endothelial cells.
318 Unlike UL148, which resides in the ER, US16 localizes to the cytoplasmic viral assembly compartment
319 (cVAC), where virions acquire their infectious envelope. How US16 promotes pentamer
320 incorporation is unclear, but co-immunoprecipitation results suggest that US16 interacts with the
321 pentamer subunit UL130. The observation that US16 localizes to – and presumably functions at the
322 cVAC may suggest that the trans-Golgi network-derived vesicles that provide virion envelopes are
323 heterogeneous. Alternatively, US16 may regulate processes by which lysosomes that localize to the
324 cVAC during infection degrade pentamer complexes, or otherwise make them unavailable for
325 incorporation into virions.

326 It is intriguing to speculate that gene products like US16 and UL148 might play tissue specific
327 roles in modulating the composition of viral gH/gL complexes in vivo. Since production of
328 pentamer-rich pools of gH/gL might favor cell-associated modes of spread that evade humoral
329 immunity, while trimer-rich particles could provide a fitness advantage during horizontal shedding,
330 it would be crucial to identify how viral modulators of these complexes might be regulated. It would
331 be helpful to know, for instance, whether virions with increased levels of trimer are produced in
332 saliva or breast milk during natural infection.

333 In the example of EBV, a viral tropism switch that drives alternating cycles of viral replication
334 in B-cells and epithelial cells depends on the cell type producing virus to regulate the levels in
335 progeny virions of gH/gL and gH/gL/gp42, the latter being required for infection of B-cells [91].
336 Although there is at least one report that gH/gL composition and that the degree of heterogeneity in
337 the cell tropism of progeny virions depends on the cell type producing virus [1], additional research
338 in this area is certainly warranted. Regardless, if one or more bona fide tropism switches exists in
339 HCMV, the mechanisms are likely to differ from those found in EBV.

340 **Conclusion and Outlook.**

341 Although the processes by which HCMV enters human cells and navigates through the human
342 body remain to be fully understood, crucial new information on the cellular receptors and viral entry
343 machinery has shed new light on HCMV entry and cell tropism. It is hoped that the coming decade
344 will see investigators leverage these advances to develop new therapies to limit disease, as well as to
345 reveal how HCMV spreads through the host to establish infection at sites of latency, long-term
346 persistence, and horizontal shedding.

347 **ACKNOWLEDGEMENTS:** Research in the Kamil Laboratory is supported by grants R01-AI116851 and P30-
348 GM110703 from the National Institutes of Health. This content is solely the responsibility of the authors and
349 does not necessarily represent the official views of the National Institutes of Health. C.C.N. is supported by a
350 Malcolm Feist Fellowship in the Cardiovascular Sciences.

351

352 **REFERENCES.**

- 353 1. Scrivano, L.; Sinzger, C.; Nitschko, H.; Koszinowski, U.H.; Adler, B. HCMV spread and cell tropism are
354 determined by distinct virus populations. *PLoS Pathog.* **2011**, *7*, e1001256.
- 355 2. Chee, M.S.; Bankier, A.T.; Beck, S.; Bohni, R.; Brown, C.M.; Cerny, R.; Horsnell, T.; Hutchison, C.A., 3rd;
356 Kouzarides, T.; Martignetti, J.A., et al. Analysis of the protein-coding content of the sequence of human
357 cytomegalovirus strain AD169. *Curr. Top. Microbiol. Immunol.* **1990**, *154*, 125-169.
- 358 3. Britt, W.J. Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of
359 human cytomegalovirus. *Virology* **1984**, *135*, 369-378.
- 360 4. Gretch, D.R.; Kari, B.; Rasmussen, L.; Gehrz, R.C.; Stinski, M.F. Identification and characterization of three
361 distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus. *J. Virol.* **1988**, *62*,
362 875-881.
- 363 5. Gretch, D.R.; Gehrz, R.C.; Stinski, M.F. Characterization of a human cytomegalovirus glycoprotein complex
364 (gcI). *J. Gen. Virol.* **1988**, *69* (Pt 6), 1205-1215.
- 365 6. Calo, S.; Cortese, M.; Ciferri, C.; Bruno, L.; Gerrein, R.; Benucci, B.; Monda, G.; Gentile, M.; Kessler, T.;
366 Uematsu, Y., et al. The Human Cytomegalovirus UL116 Gene Encodes an Envelope Glycoprotein Forming
367 a Complex with gH Independently from gL. *J. Virol.* **2016**, *90*, 4926-4938.
- 368 7. Heldwein, E.E.; Lou, H.; Bender, F.C.; Cohen, G.H.; Eisenberg, R.J.; Harrison, S.C. Crystal structure of
369 glycoprotein B from herpes simplex virus 1. *Science* **2006**, *313*, 217-220.
- 370 8. Chandramouli, S.; Ciferri, C.; Nikitin, P.A.; Calo, S.; Gerrein, R.; Balabanis, K.; Monroe, J.; Hebner, C.; Lilja,
371 A.E.; Settembre, E.C., et al. Structure of HCMV glycoprotein B in the postfusion conformation bound to a
372 neutralizing human antibody. *Nat Commun* **2015**, *6*, 8176.
- 373 9. Harrison, S.C. Viral membrane fusion. *Virology* **2015**, *479-480*, 498-507.
- 374 10. Roche, S.; Albertini, A.A.; Lepault, J.; Bressanelli, S.; Gaudin, Y. Structures of vesicular stomatitis virus
375 glycoprotein: membrane fusion revisited. *Cell. Mol. Life Sci.* **2008**, *65*, 1716-1728.
- 376 11. Britt, W.J.; Auger, D. Synthesis and processing of the envelope gp55-116 complex of human
377 cytomegalovirus. *J. Virol.* **1986**, *58*, 185-191.
- 378 12. Burke, H.G.; Heldwein, E.E. Crystal Structure of the Human Cytomegalovirus Glycoprotein B. *PLoS Pathog.*
379 **2015**, *11*, e1005227.
- 380 13. Wang, X.; Huong, S.M.; Chiu, M.L.; Raab-Traub, N.; Huang, E.S. Epidermal growth factor receptor is a
381 cellular receptor for human cytomegalovirus. *Nature* **2003**, *424*, 456-461.
- 382 14. Soroceanu, L.; Akhavan, A.; Cobbs, C.S. Platelet-derived growth factor- α receptor activation is
383 required for human cytomegalovirus infection. *Nature* **2008**, *455*, 391-395.
- 384 15. Feire, A.L.; Roy, R.M.; Manley, K.; Compton, T. The glycoprotein B disintegrin-like domain binds beta 1
385 integrin to mediate cytomegalovirus entry. *J. Virol.* **2010**, *84*, 10026-10037.
- 386 16. Feire, A.L.; Koss, H.; Compton, T. Cellular integrins function as entry receptors for human cytomegalovirus
387 via a highly conserved disintegrin-like domain. *Proc. Natl. Acad. Sci. U. S. A.* **2004**, *101*, 15470-15475.
- 388 17. Wille, P.T.; Wisner, T.W.; Ryckman, B.; Johnson, D.C. Human cytomegalovirus (HCMV) glycoprotein gB
389 promotes virus entry in trans acting as the viral fusion protein rather than as a receptor-binding protein.
390 *MBio* **2013**, *4*, e00332-00313.
- 391 18. Mach, M.; Kropff, B.; Dal Monte, P.; Britt, W. Complex formation by human cytomegalovirus glycoproteins
392 M (gpUL100) and N (gpUL73). *J. Virol.* **2000**, *74*, 11881-11892.
- 393 19. Mach, M.; Kropff, B.; Kryzaniak, M.; Britt, W. Complex formation by glycoproteins M and N of human
394 cytomegalovirus: structural and functional aspects. *J. Virol.* **2005**, *79*, 2160-2170.
- 395 20. Kropff, B.; Burkhardt, C.; Schott, J.; Nentwich, J.; Fisch, T.; Britt, W.; Mach, M. Glycoprotein N of human
396 cytomegalovirus protects the virus from neutralizing antibodies. *PLoS Pathog.* **2012**, *8*, e1002999.
- 397 21. Varnum, S.M.; Streblow, D.N.; Monroe, M.E.; Smith, P.; Auberry, K.J.; Pasa-Tolic, L.; Wang, D.; Camp, D.G.,
398 2nd; Rodland, K.; Wiley, S., et al. Identification of proteins in human cytomegalovirus (HCMV) particles:
399 the HCMV proteome. *J. Virol.* **2004**, *78*, 10960-10966.
- 400 22. Kari, B.; Gehrz, R. A human cytomegalovirus glycoprotein complex designated gC-II is a major heparin-
401 binding component of the envelope. *J. Virol.* **1992**, *66*, 1761-1764.
- 402 23. Krzyzaniak, M.; Mach, M.; Britt, W.J. The cytoplasmic tail of glycoprotein M (gpUL100) expresses
403 trafficking signals required for human cytomegalovirus assembly and replication. *J. Virol.* **2007**, *81*, 10316-
404 10328.

- 405 24. Mach, M.; Osinski, K.; Kropff, B.; Schloetzer-Schrehardt, U.; Krzyzaniak, M.; Britt, W. The carboxy-terminal
406 domain of glycoprotein N of human cytomegalovirus is required for virion morphogenesis. *J. Virol.* **2007**,
407 *81*, 5212-5224.
- 408 25. Renzette, N.; Bhattacharjee, B.; Jensen, J.D.; Gibson, L.; Kowalik, T.F. Extensive genome-wide variability of
409 human cytomegalovirus in congenitally infected infants. *PLoS Pathog.* **2011**, *7*, e1001344.
- 410 26. Pignatelli, S.; Dal Monte, P.; Rossini, G.; Chou, S.; Gojobori, T.; Hanada, K.; Guo, J.J.; Rawlinson, W.; Britt,
411 W.; Mach, M., et al. Human cytomegalovirus glycoprotein N (gpUL73-gN) genomic variants: identification
412 of a novel subgroup, geographical distribution and evidence of positive selective pressure. *J. Gen. Virol.*
413 **2003**, *84*, 647-655.
- 414 27. Shimamura, M.; Mach, M.; Britt, W.J. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-
415 specific virus-neutralizing antibody response. *J. Virol.* **2006**, *80*, 4591-4600.
- 416 28. Ciferri, C.; Chandramouli, S.; Donnarumma, D.; Nikitin, P.A.; Cianfrocco, M.A.; Gerrein, R.; Feire, A.L.;
417 Barnett, S.W.; Lilja, A.E.; Rappuoli, R., et al. Structural and biochemical studies of HCMV gH/gL/gO and
418 Pentamer reveal mutually exclusive cell entry complexes. *Proc. Natl. Acad. Sci. U. S. A.* **2015**,
419 *10.1073/pnas.1424818112*.
- 420 29. Huber, M.T.; Compton, T. Characterization of a novel third member of the human cytomegalovirus
421 glycoprotein H-glycoprotein L complex. *J. Virol.* **1997**, *71*, 5391-5398.
- 422 30. Huber, M.T.; Compton, T. The human cytomegalovirus UL74 gene encodes the third component of the
423 glycoprotein H-glycoprotein L-containing envelope complex. *J. Virol.* **1998**, *72*, 8191-8197.
- 424 31. Jiang, X.J.; Adler, B.; Sampaio, K.L.; Digel, M.; Jahn, G.; Ettischer, N.; Stierhof, Y.D.; Scrivano, L.;
425 Koszinowski, U.; Mach, M., et al. UL74 of human cytomegalovirus contributes to virus release by
426 promoting secondary envelopment of virions. *J. Virol.* **2008**, *82*, 2802-2812.
- 427 32. Zhou, M.; Lanchy, J.M.; Ryckman, B.J. Human Cytomegalovirus gH/gL/gO Promotes the Fusion Step of
428 Entry into All Cell Types, whereas gH/gL/UL128-131 Broadens Virus Tropism through a Distinct
429 Mechanism. *J. Virol.* **2015**, *89*, 8999-9009.
- 430 33. Kabanova, A.; Marcandalli, J.; Zhou, T.; Bianchi, S.; Baxa, U.; Tsybovsky, Y.; Lillier, D.; Silacci-Fregni, C.;
431 Foglierini, M.; Fernandez-Rodriguez, B.M., et al. Platelet-derived growth factor-alpha receptor is the
432 cellular receptor for human cytomegalovirus gHgLgO trimer. *Nat Microbiol* **2016**, *1*, 16082.
- 433 34. Wu, Y.; Prager, A.; Boos, S.; Resch, M.; Brizic, I.; Mach, M.; Wildner, S.; Scrivano, L.; Adler, B. Human
434 cytomegalovirus glycoprotein complex gH/gL/gO uses PDGFR-alpha as a key for entry. *PLoS Pathog.* **2017**,
435 *13*, e1006281.
- 436 35. Stegmann, C.; Hochdorfer, D.; Lieber, D.; Subramanian, N.; Stohr, D.; Laib Sampaio, K.; Sinzger, C. A
437 derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus
438 and inhibits entry into fibroblasts and endothelial cells. *PLoS Pathog.* **2017**, *13*, e1006273.
- 439 36. Wu, K.; Oberstein, A.; Wang, W.; Shenk, T. Role of PDGF receptor-alpha during human cytomegalovirus
440 entry into fibroblasts. *Proc. Natl. Acad. Sci. U. S. A.* **2018**, *10.1073/pnas.1806305115*.
- 441 37. Martinez-Martin, N.; Marcandalli, J.; Huang, C.S.; Arthur, C.P.; Perotti, M.; Foglierini, M.; Ho, H.; Dosey,
442 A.M.; Shriver, S.; Payandeh, J., et al. An Unbiased Screen for Human Cytomegalovirus Identifies
443 Neuropilin-2 as a Central Viral Receptor. *Cell* **2018**, *174*, 1158-1171 e1119.
- 444 38. Wille, P.T.; Knoche, A.J.; Nelson, J.A.; Jarvis, M.A.; Johnson, D.C. A human cytomegalovirus gO-null
445 mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial
446 and endothelial cells. *J. Virol.* **2010**, *84*, 2585-2596.
- 447 39. Liu, J.; Jardetzky, T.S.; Chin, A.L.; Johnson, D.C.; Vanarsdall, A.L. The human cytomegalovirus trimer and
448 pentamer promote sequential steps in entry into epithelial and endothelial cells at cell surfaces and
449 endosomes. *J. Virol.* **2018**, *10.1128/JVI.01336-18*.
- 450 40. Wang, D.; Shenk, T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell
451 tropism. *J. Virol.* **2005**, *79*, 10330-10338.
- 452 41. Wang, D.; Shenk, T. Human cytomegalovirus virion protein complex required for epithelial and
453 endothelial cell tropism. *Proc. Natl. Acad. Sci. U. S. A.* **2005**, *102*, 18153-18158.
- 454 42. Ryckman, B.J.; Rainish, B.L.; Chase, M.C.; Borton, J.A.; Nelson, J.A.; Jarvis, M.A.; Johnson, D.C.
455 Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into
456 epithelial and endothelial cells. *J. Virol.* **2008**, *82*, 60-70.

- 457 43. Chandramouli, S.; Malito, E.; Nguyen, T.; Luisi, K.; Donnarumma, D.; Xing, Y.; Norais, N.; Yu, D.; Carfi, A.
458 Structural basis for potent antibody-mediated neutralization of human cytomegalovirus. *Sci Immunol* **2017**,
459 2.
- 460 44. Akter, P.; Cunningham, C.; McSharry, B.P.; Dolan, A.; Addison, C.; Dargan, D.J.; Hassan-Walker, A.F.;
461 Emery, V.C.; Griffiths, P.D.; Wilkinson, G.W., et al. Two novel spliced genes in human cytomegalovirus. *J.*
462 *Gen. Virol.* **2003**, *84*, 1117-1122.
- 463 45. Hahn, G.; Revello, M.G.; Patrone, M.; Percivalle, E.; Campanini, G.; Sarasini, A.; Wagner, M.; Gallina, A.;
464 Milanesi, G.; Koszinowski, U., et al. Human cytomegalovirus UL131-128 genes are indispensable for virus
465 growth in endothelial cells and virus transfer to leukocytes. *J. Virol.* **2004**, *78*, 10023-10033.
- 466 46. Adler, B.; Scrivano, L.; Ruzcics, Z.; Rupp, B.; Sinzger, C.; Koszinowski, U. Role of human cytomegalovirus
467 UL131A in cell type-specific virus entry and release. *J. Gen. Virol.* **2006**, *87*, 2451-2460.
- 468 47. Patrone, M.; Secchi, M.; Fiorina, L.; Ierardi, M.; Milanesi, G.; Gallina, A. Human cytomegalovirus UL130
469 protein promotes endothelial cell infection through a producer cell modification of the virion. *J. Virol.* **2005**,
470 *79*, 8361-8373.
- 471 48. Gerna, G.; Percivalle, E.; Lilleri, D.; Lozza, L.; Fornara, C.; Hahn, G.; Baldanti, F.; Revello, M.G. Dendritic-
472 cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and
473 mediates efficient viral antigen presentation to CD8+ T cells. *J. Gen. Virol.* **2005**, *86*, 275-284.
- 474 49. Ciferri, C.; Chandramouli, S.; Leitner, A.; Donnarumma, D.; Cianfrocco, M.A.; Gerrein, R.; Friedrich, K.;
475 Aggarwal, Y.; Palladino, G.; Aebersold, R., et al. Antigenic Characterization of the HCMV gH/gL/gO and
476 Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human Antibodies. *PLoS*
477 *Pathog.* **2015**, *11*, e1005230.
- 478 50. Malkowska, M.; Kokoszynska, K.; Dymecka, M.; Rychlewski, L.; Wyrwicz, L.S. Alphaherpesvirinae and
479 Gammaherpesvirinae glycoprotein L and CMV UL130 originate from chemokines. *Virol J.* **2013**, *10*, 1.
- 480 51. Stampfer, S.D.; Heldwein, E.E. Stuck in the middle: structural insights into the role of the gH/gL
481 heterodimer in herpesvirus entry. *Curr. Opin. Virol.* **2013**, *3*, 13-19.
- 482 52. Baldanti, F.; Paolucci, S.; Campanini, G.; Sarasini, A.; Percivalle, E.; Revello, M.G.; Gerna, G. Human
483 cytomegalovirus UL131A, UL130 and UL128 genes are highly conserved among field isolates. *Arch. Virol.*
484 **2006**, *151*, 1225-1233.
- 485 53. Novotny, J.; Rigoutsos, I.; Coleman, D.; Shenk, T. In silico structural and functional analysis of the human
486 cytomegalovirus (HHV5) genome. *J. Mol. Biol.* **2001**, *310*, 1151-1166.
- 487 54. Vanarsdall, A.L.; Pritchard, S.R.; Wisner, T.W.; Liu, J.; Jardetzky, T.S.; Johnson, D.C. CD147 Promotes Entry
488 of Pentamer-Expressing Human Cytomegalovirus into Epithelial and Endothelial Cells. *MBio* **2018**, *9*.
- 489 55. Raaben, M.; Jae, L.T.; Herbert, A.S.; Kuehne, A.I.; Stubbs, S.H.; Chou, Y.Y.; Blomen, V.A.; Kirchhausen, T.;
490 Dye, J.M.; Brummelkamp, T.R., et al. NRP2 and CD63 Are Host Factors for Lujo Virus Cell Entry. *Cell Host*
491 *Microbe* **2017**, *22*, 688-696 e685.
- 492 56. Hochdorfer, D.; Florin, L.; Sinzger, C.; Lieber, D. Tetraspanin CD151 Promotes Initial Events in Human
493 Cytomegalovirus Infection. *J. Virol.* **2016**, *90*, 6430-6442.
- 494 57. Li, Q.; Wilkie, A.R.; Weller, M.; Liu, X.; Cohen, J.I. THY-1 Cell Surface Antigen (CD90) Has an Important
495 Role in the Initial Stage of Human Cytomegalovirus Infection. *PLoS Pathog.* **2015**, *11*, e1004999.
- 496 58. Li, Q.; Fischer, E.; Cohen, J.I. Cell Surface THY-1 Contributes to Human Cytomegalovirus Entry via a
497 Macropinocytosis-Like Process. *J. Virol.* **2016**, *90*, 9766-9781.
- 498 59. Wang, X.; Huang, D.Y.; Huong, S.M.; Huang, E.S. Integrin alphavbeta3 is a coreceptor for human
499 cytomegalovirus. *Nat. Med.* **2005**, *11*, 515-521.
- 500 60. Nogalski, M.T.; Chan, G.; Stevenson, E.V.; Gray, S.; Yurochko, A.D. Human cytomegalovirus-regulated
501 paxillin in monocytes links cellular pathogenic motility to the process of viral entry. *J. Virol.* **2011**, *85*, 1360-
502 1369.
- 503 61. Grove, J.; Marsh, M. The cell biology of receptor-mediated virus entry. *J. Cell Biol.* **2011**, *195*, 1071-1082.
- 504 62. Compton, T.; Nepomuceno, R.R.; Nowlin, D.M. Human cytomegalovirus penetrates host cells by pH-
505 independent fusion at the cell surface. *Virology* **1992**, *191*, 387-395.
- 506 63. Ryckman, B.J.; Jarvis, M.A.; Drummond, D.D.; Nelson, J.A.; Johnson, D.C. Human cytomegalovirus entry
507 into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-
508 pH fusion. *J. Virol.* **2006**, *80*, 710-722.
- 509 64. Hetzenecker, S.; Helenius, A.; Krzyzaniak, M.A. HCMV Induces Macropinocytosis for Host Cell Entry in
510 Fibroblasts. *Traffic* **2016**, *17*, 351-368.

- 511 65. Nogalski, M.T.; Chan, G.C.; Stevenson, E.V.; Collins-McMillen, D.K.; Yurochko, A.D. The HCMV
512 gH/gL/UL128-131 complex triggers the specific cellular activation required for efficient viral internalization
513 into target monocytes. *PLoS Pathog.* **2013**, *9*, e1003463.
- 514 66. Atanasiu, D.; Whitbeck, J.C.; de Leon, M.P.; Lou, H.; Hannah, B.P.; Cohen, G.H.; Eisenberg, R.J. Bimolecular
515 complementation defines functional regions of Herpes simplex virus gB that are involved with gH/gL as a
516 necessary step leading to cell fusion. *J. Virol.* **2010**, *84*, 3825-3834.
- 517 67. Avitabile, E.; Forghieri, C.; Campadelli-Fiume, G. Complexes between herpes simplex virus glycoproteins
518 gD, gB, and gH detected in cells by complementation of split enhanced green fluorescent protein. *J. Virol.*
519 **2007**, *81*, 11532-11537.
- 520 68. Cairns, T.M.; Whitbeck, J.C.; Lou, H.; Heldwein, E.E.; Chowdary, T.K.; Eisenberg, R.J.; Cohen, G.H.
521 Capturing the herpes simplex virus core fusion complex (gB-gH/gL) in an acidic environment. *J. Virol.* **2011**,
522 *85*, 6175-6184.
- 523 69. Vanarsdall, A.L.; Howard, P.W.; Wisner, T.W.; Johnson, D.C. Human Cytomegalovirus gH/gL Forms a
524 Stable Complex with the Fusion Protein gB in Virions. *PLoS Pathog.* **2016**, *12*, e1005564.
- 525 70. Bowden, R.A.; Slichter, S.J.; Sayers, M.; Weisdorf, D.; Cays, M.; Schoch, G.; Banaji, M.; Haake, R.; Welk, K.;
526 Fisher, L., et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative
527 blood products for the prevention of transfusion-associated CMV infection after marrow transplant. *Blood*
528 **1995**, *86*, 3598-3603.
- 529 71. Lipson, S.M.; Shepp, D.H.; Match, M.E.; Axelrod, F.B.; Whitbread, J.A. Cytomegalovirus infectivity in
530 whole blood following leukocyte reduction by filtration. *Am. J. Clin. Pathol.* **2001**, *116*, 52-55.
- 531 72. Spector, S.A.; Hsia, K.; Crager, M.; Pilcher, M.; Cabral, S.; Stempien, M.J. Cytomegalovirus (CMV) DNA
532 load is an independent predictor of CMV disease and survival in advanced AIDS. *J. Virol.* **1999**, *73*, 7027-
533 7030.
- 534 73. Sinzger, C.; Schmidt, K.; Knapp, J.; Kahl, M.; Beck, R.; Waldman, J.; Hebart, H.; Einsele, H.; Jahn, G.
535 Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes
536 in the viral genome. *The Journal of general virology* **1999**, *80* (Pt 11), 2867-2877.
- 537 74. Yamane, Y.; Furukawa, T.; Plotkin, S.A. Supernatant virus release as a differentiating marker between low
538 passage and vaccine strains of human cytomegalovirus. *Vaccine* **1983**, *1*, 23-25.
- 539 75. Dargan, D.J.; Douglas, E.; Cunningham, C.; Jamieson, F.; Stanton, R.J.; Baluchova, K.; McSharry, B.P.;
540 Tomasec, P.; Emery, V.C.; Percivalle, E., et al. Sequential mutations associated with adaptation of human
541 cytomegalovirus to growth in cell culture. *J. Gen. Virol.* **2010**, *91*, 1535-1546.
- 542 76. Stanton, R.J.; Baluchova, K.; Dargan, D.J.; Cunningham, C.; Sheehy, O.; Seirafian, S.; McSharry, B.P.; Neale,
543 M.L.; Davies, J.A.; Tomasec, P., et al. Reconstruction of the complete human cytomegalovirus genome in a
544 BAC reveals RL13 to be a potent inhibitor of replication. *J. Clin. Invest.* **2010**, *120*, 3191-3208.
- 545 77. Cortese, M.; Calo, S.; D'Aurizio, R.; Lilja, A.; Pacchiani, N.; Merola, M. Recombinant human
546 cytomegalovirus (HCMV) RL13 binds human immunoglobulin G Fc. *PLoS One* **2012**, *7*, e50166.
- 547 78. Laib Sampaio, K.; Stegmann, C.; Brizic, I.; Adler, B.; Stanton, R.J.; Sinzger, C. The contribution of pUL74 to
548 growth of human cytomegalovirus is masked in the presence of RL13 and UL128 expression. *The Journal of*
549 *general virology* **2016**, *97*, 1917-1927.
- 550 79. Murrell, I.; Bedford, C.; Ladell, K.; Miners, K.L.; Price, D.A.; Tomasec, P.; Wilkinson, G.W.G.; Stanton, R.J.
551 The pentameric complex drives immunologically covert cell-cell transmission of wild-type human
552 cytomegalovirus. *Proc. Natl. Acad. Sci. U. S. A.* **2017**, *114*, 6104-6109.
- 553 80. Silva, M.C.; Schroer, J.; Shenk, T. Human cytomegalovirus cell-to-cell spread in the absence of an essential
554 assembly protein. *Proc. Natl. Acad. Sci. U. S. A.* **2005**, *102*, 2081-2086.
- 555 81. Zhou, M.; Yu, Q.; Wechsler, A.; Ryckman, B.J. Comparative analysis of gO isoforms reveals that strains of
556 human cytomegalovirus differ in the ratio of gH/gL/gO and gH/gL/UL128-131 in the virion envelope. *J.*
557 *Virol.* **2013**, *87*, 9680-9690.
- 558 82. Murphy, E.; Yu, D.; Grimwood, J.; Schmutz, J.; Dickson, M.; Jarvis, M.A.; Hahn, G.; Nelson, J.A.; Myers,
559 R.M.; Shenk, T.E. Coding potential of laboratory and clinical strains of human cytomegalovirus. *Proc. Natl.*
560 *Acad. Sci. U. S. A.* **2003**, *100*, 14976-14981.
- 561 83. Sinzger, C.; Hahn, G.; Digel, M.; Katona, R.; Sampaio, K.L.; Messerle, M.; Hengel, H.; Koszinowski, U.;
562 Brune, W.; Adler, B. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived
563 from human cytomegalovirus TB40/E. *J. Gen. Virol.* **2008**, *89*, 359-368.

- 564 84. Hahn, G.; Khan, H.; Baldanti, F.; Koszinowski, U.H.; Revello, M.G.; Gerna, G. The human cytomegalovirus
565 ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a
566 BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. *J. Virol.*
567 **2002**, *76*, 9551-9555.
- 568 85. Murrell, I.; Tomasec, P.; Wilkie, G.S.; Dargan, D.J.; Davison, A.J.; Stanton, R.J. Impact of sequence variation
569 in the UL128 locus on production of human cytomegalovirus in fibroblast and epithelial cells. *J. Virol.* **2013**,
570 *87*, 10489-10500.
- 571 86. Li, G.; Nguyen, C.C.; Ryckman, B.J.; Britt, W.J.; Kamil, J.P. A viral regulator of glycoprotein complexes
572 contributes to human cytomegalovirus cell tropism. *Proc. Natl. Acad. Sci. U. S. A.* **2015**, *112*, 4471-4476.
- 573 87. Nguyen, C.C.; Siddiquey, M.N.A.; Zhang, H.; Li, G.; Kamil, J.P. Human Cytomegalovirus Tropism
574 Modulator UL148 Interacts with SEL1L, a Cellular Factor That Governs Endoplasmic Reticulum-
575 Associated Degradation of the Viral Envelope Glycoprotein gO. *J. Virol.* **2018**, *92*.
- 576 88. Wang, E.C.Y.; Pjehova, M.; Nightingale, K.; Vlahava, V.M.; Patel, M.; Ruckova, E.; Forbes, S.K.; Nobre, L.;
577 Antrobus, R.; Roberts, D., et al. Suppression of costimulation by human cytomegalovirus promotes evasion
578 of cellular immune defenses. *Proc. Natl. Acad. Sci. U. S. A.* **2018**, *115*, 4998-5003.
- 579 89. Siddiquey, M.N.A.; Zhang, H.; Nguyen, C.C.; Domma, A.J.; Kamil, J.P. The Human Cytomegalovirus
580 Endoplasmic Reticulum-Resident Glycoprotein UL148 Activates the Unfolded Protein Response. *J. Virol.*
581 **2018**, *92*.
- 582 90. Lugini, A.; Cavaletto, N.; Raimondo, S.; Geuna, S.; Gribaudo, G. Loss of the Human Cytomegalovirus
583 US16 Protein Abrogates Virus Entry into Endothelial and Epithelial Cells by Reducing the Virion Content
584 of the Pentamer. *J. Virol.* **2017**, *91*.
- 585 91. Borza, C.M.; Hutt-Fletcher, L.M. Alternate replication in B cells and epithelial cells switches tropism of
586 Epstein-Barr virus. *Nat. Med.* **2002**, *8*, 594-599.
587